Outcomes following TLI-based, TBI-based, or ATS/CTX conditioning and MHC-mismatched BMT for murine β-thal
| Conditioning . | N . | Engraftment, n (%)*,† . | Rejection, n (%)‡,§ . | GVHD, n (%)§ . | Day 100 engraftment; no GVHD, n (%)† . |
|---|---|---|---|---|---|
| TBI300/ATS/CTX | 8 | 5 (62.5) | 2 (40.0) | 3 (60.0) | 0 |
| TBI 600/ATS/CTX | 9 | 7 (77.7) | 3 (42.8) | 1 (14.3) | 3 (33.3) |
| TBI 800/ATS/CTX | 11 | 11 (100) | 1 (9.1) | 7 (63.6) | 3 (27.3) |
| TBI 1200/ATS/CTX | 11 | 11 (100) | 0 | 9 (81.8) | 2 (18.2) |
| TBI 1200/CTX | 7 | 7 (100) | 0 | 7 (100) | 0 |
| ATS/CTX | 10 | 0 | 0 | 0 | 0 |
| TLI/CTX | 6 | 5 (83.3) | 0 | 3 (60.0) | 1 (16.7) |
| TLI/ATS | 14 | 13 (92.8) | 4 (30.8) | 4 (30.8) | 4 (28.6) |
| TLI/ATS/CTX | 10 | 10 (100) | 0 | 0 | 10 (100) |
| Conditioning . | N . | Engraftment, n (%)*,† . | Rejection, n (%)‡,§ . | GVHD, n (%)§ . | Day 100 engraftment; no GVHD, n (%)† . |
|---|---|---|---|---|---|
| TBI300/ATS/CTX | 8 | 5 (62.5) | 2 (40.0) | 3 (60.0) | 0 |
| TBI 600/ATS/CTX | 9 | 7 (77.7) | 3 (42.8) | 1 (14.3) | 3 (33.3) |
| TBI 800/ATS/CTX | 11 | 11 (100) | 1 (9.1) | 7 (63.6) | 3 (27.3) |
| TBI 1200/ATS/CTX | 11 | 11 (100) | 0 | 9 (81.8) | 2 (18.2) |
| TBI 1200/CTX | 7 | 7 (100) | 0 | 7 (100) | 0 |
| ATS/CTX | 10 | 0 | 0 | 0 | 0 |
| TLI/CTX | 6 | 5 (83.3) | 0 | 3 (60.0) | 1 (16.7) |
| TLI/ATS | 14 | 13 (92.8) | 4 (30.8) | 4 (30.8) | 4 (28.6) |
| TLI/ATS/CTX | 10 | 10 (100) | 0 | 0 | 10 (100) |
Cumulative incidence of primary engraftment, graft rejection, GVHD, non-GVHD death, and day 100 engrafted survival without GVHD, stratified by treatment group. Data summarize n = 28 experiments.
Defined as >10% donor engraftment in at least 2 of 3 lineages at day 28, or assumed engrafted by histologic confirmation of hyperacute GVHD lethal before day 28 in some myeloablated controls.
Percentage of total mice in each treatment group.
Secondary rejection requires confirmation of primary engraftment on day 28.
Percentage of total engrafting mice in each treatment group. GVHD defined by blinded histopathologic cumulative GVHD score >1, regardless of primary cause of death.